(Total Views: 313)
Posted On: 05/10/2018 1:08:27 PM
Post# of 72440
Re: someconcerns #45614
I could see this at $18 - $36+ in time.
1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types
https://finance.yahoo.com/news/lilly-announce...00916.html
1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types
https://finance.yahoo.com/news/lilly-announce...00916.html
(1)
(0)Scroll down for more posts ▼
